Open Nav

Click Therapeutics, Inc.

  • David B. Klein, Click Therapeutics, Inc.

Gain visibility amongst biotech innovators and investors

  • Date:Thursday, October 18
  • Time:9:30 AM - 9:45 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.
  • Company
  • Company HQ City:New York, NY
  • Company HQ Country:United States
  • Company HQ State:New York                    
  • CEO/Top Company Official:David Benshoof Klein
  • Year Founded:2012
  • Main Therapeutic Focus:Digital Health
  • Lead Product in Development :CT-152: Digital Therapeutic for Major Depressive Disorder in Adults
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :4
  • Previous and Current Investors:Sanofi Ventures, Magellan Health
  • Size of Last Investment Round:$17 million
  • Total Amount Raised to Date, In All Rounds:$20 million
David B. Klein
Click Therapeutics, Inc.